A share price of Biogen Inc [BIIB] is currently trading at $134.46, up 3.33%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BIIB shares have gain 7.06% over the last week, with a monthly amount glided 3.15%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on April 28, 2025, when HSBC Securities downgraded its rating to a Hold but kept the price target unchanged to $118 for it. Previously, Argus downgraded its rating to Hold on April 04, 2025. On February 11, 2025, Bernstein initiated with a Mkt Perform rating and assigned a price target of $160 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $138 on January 02, 2025. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $164 on December 20, 2024. Stifel downgraded its rating to Hold for this stock on December 16, 2024, but kept the price target unchanged to $175.
Biogen Inc experienced fluctuations in its stock price throughout the past year between $110.04 and $238.00. Currently, Wall Street analysts expect the stock to reach $197.88 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $134.46 at the most recent close of the market. An investor can expect a potential return of 47.17% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
Trailing Twelve Months sales for Biogen Inc [NASDAQ:BIIB] were 9.40B which represents 6.17% growth. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at 0.23%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.09 and Total Capital is 0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 131.33 points at the first support level, and at 128.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 136.59, and for the 2nd resistance point, it is at 138.71.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Biogen Inc [NASDAQ:BIIB] is 1.44. As well, the Quick Ratio is 1.01, while the Cash Ratio is 0.49. Considering the valuation of this stock, the price to sales ratio is 2.10, the price to book ratio is 1.16 and price to earnings (TTM) ratio is 13.28.
Transactions by insiders
Recent insider trading involved Izzar Rachid, Officer, that happened on Jul 08 ’25 when 2223.0 shares were purchased. Head of Development, Singhal Priya completed a deal on May 19 ’25 to sell 3806.0 shares. Meanwhile, Officer Singhal Priya bought 3806.0 shares on May 19 ’25.
